Durect’s post-op painkiller splits FDA advisory panelAs the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new Share XDurect’s post-op painkiller splits FDA advisory panelhttps://pharmaphorum.com/news/durects-post-op-painkiller-splits-fda-advisory-panel/
Nektar pulls pain drug after bruising FDA panel meetingNektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory Share XNektar pulls pain drug after bruising FDA panel meetinghttps://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/
Blueprint gets first approval as FDA backs stomach cancer drugUS biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for Share XBlueprint gets first approval as FDA backs stomach cancer drughttps://pharmaphorum.com/news/blueprint-gets-first-approval-as-fda-backs-stomach-cancer-drug/
Newron plots phase 3 trial of schizophrenia drug after safety scareNewron Pharmaceuticals has clearance to press ahead with phase 3 development of its schizophrenia drug Evenamide after the Share XNewron plots phase 3 trial of schizophrenia drug after safety scarehttps://pharmaphorum.com/news/newron-plots-phase-3-trial-of-schizophrenia-drug-after-safety-scare/
Merck claims first-ever FDA approval for an Ebola vaccineMerck & Co’s Ebola vaccine Ervebo has been cleared for marketing in the US, just weeks after getting Share XMerck claims first-ever FDA approval for an Ebola vaccinehttps://pharmaphorum.com/news/merck-claims-first-ever-fda-approval-for-an-ebola-vaccine/
FDA takes another step to encourage copycat insulin productsThe FDA has made another move to allow biosimilars get to market in the US more quickly, this Share XFDA takes another step to encourage copycat insulin productshttps://pharmaphorum.com/news/fda-takes-another-step-to-encourage-copycat-insulin-products/
Epizyme’s sarcoma drug tazemetostat faces key vote from FDA advisersEpizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed Share XEpizyme’s sarcoma drug tazemetostat faces key vote from FDA advisershttps://pharmaphorum.com/news/epizymes-sarcoma-drug-tazemetostat-faces-key-vote-from-fda-advisers/
The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
Senate committee backs Hahn as new FDA CommissionerPresident Trump’s pick for the new FDA Commissioner – Stephen Hahn – has picked up the endorsement he Share XSenate committee backs Hahn as new FDA Commissionerhttps://pharmaphorum.com/news/senate-committee-backs-hahn-as-new-fda-commissioner/
